Drug-Induced Gingival Overgrowth in Dentistry

Topic: Drug-induced gingival overgrowth / medication-induced gingival enlargement

German terms: medikamenteninduzierte Gingivahyperplasie, Gingivawucherung, Gingivavergrößerung

Classic drug groups: Anticonvulsants such as phenytoin, immunosuppressants such as cyclosporine, and calcium channel blockers such as nifedipine, amlodipine, verapamil, and diltiazem.

Key dental role: Early recognition, plaque and inflammation control, periodontal monitoring, patient education, and communication with the prescribing physician when medication review may be needed.

This article is for dental education only. A dentist should not independently stop or replace phenytoin, cyclosporine, antihypertensive drugs, or any long-term medication. Drug substitution must be discussed with the prescribing physician. The dental priority is to reduce plaque-related inflammation, assess severity, document the suspected drug association, and coordinate medical and periodontal care.

Drug-induced gingival overgrowth is an abnormal enlargement of the gingiva associated with specific systemic medications. It often begins at the interdental papillae and may progress to cover part of the crowns, create pseudo-pockets, trap plaque, impair cleaning, affect speech or chewing, and create esthetic concerns.

The enlargement is not caused by plaque alone, but plaque-related inflammation makes it worse. This is why meticulous plaque control and professional periodontal care are central even when the trigger is medication.

The key clinical principle is: do not blame the gums only and do not blame the drug only. Drug susceptibility, plaque inflammation, gingival fibroblast response, dose, duration, age, genetics, and oral hygiene all interact.

• Most classic drugs: phenytoin, cyclosporine, and nifedipine.
• Common sites: anterior gingiva and interdental papillae, often where plaque accumulation is high.
• Main dental risk: pseudo-pockets, plaque retention, bleeding, periodontitis masking, caries risk, speech problems, and esthetic concern.
• First dental response: oral hygiene instruction, professional debridement, periodontal assessment, and medication history review.
• Medical coordination: ask the prescriber whether substitution is medically possible when overgrowth is severe or recurrent.

• Anticonvulsants: phenytoin is the classic example; other antiepileptic agents have also been reported less commonly.
• Immunosuppressants: cyclosporine is strongly associated; risk may increase when combined with calcium channel blockers.
• Calcium channel blockers: nifedipine is classic, but amlodipine, verapamil, diltiazem, and other agents may be involved.
• Combination risk: patients taking cyclosporine plus nifedipine or another calcium channel blocker may show more severe overgrowth.
• Important: never stop anticonvulsants, immunosuppressants, or antihypertensives without physician involvement.

• Enlargement often begins as bead-like enlargement of interdental papillae.
• The gingiva may appear firm, fibrotic, lobulated, and pale pink when inflammation is mild.
• With plaque inflammation, tissue becomes red, swollen, bleeding, and more edematous.
• Anterior labial gingiva is commonly affected, but generalized enlargement can occur.
• Overgrowth may cover tooth surfaces and create pseudo-pockets.
• Pseudo-pockets trap plaque and make home cleaning harder.
• Severe cases can interfere with chewing, speech, eruption, orthodontic movement, and esthetics.
• Periodontal probing must distinguish true attachment loss from pseudo-pocketing.

Medication creates susceptibility, but dental plaque and gingival inflammation amplify the enlargement. A patient with excellent plaque control may have less severe inflammation and better response to treatment.

• Inflammation makes gingival enlargement more red, swollen, and bleeding.
• Overgrowth makes cleaning more difficult, which increases plaque retention.
• Plaque retention creates a cycle: more inflammation → more enlargement → harder cleaning.
• Professional debridement and home-care coaching are essential first-line steps.
• Medication substitution alone may fail if plaque control remains poor.

1. Take a complete medication history: drug name, dose, start date, changes, and indication.
2. Assess periodontal status: plaque, bleeding, probing depths, pseudo-pockets, attachment loss, mobility, furcation, and radiographs when indicated.
3. Control plaque and inflammation: oral hygiene instruction, interdental cleaning, scaling, root surface debridement, and maintenance.
4. Document severity: photos, charting, bleeding scores, pocket depths, and patient symptoms.
5. Communicate with physician: request medication review only when clinically justified; never change medication independently.
6. Re-evaluate: reassess after plaque control and possible medical adjustment.
7. Consider surgery: gingivectomy or periodontal flap surgery may be needed for persistent fibrotic enlargement.
8. Plan maintenance: recurrence is possible, especially if the drug continues and plaque control is weak.

When gingival overgrowth is moderate or severe, the dentist can write to the physician and describe the oral findings. The physician may consider an alternative drug if it is medically safe. Examples include alternative anticonvulsants, alternative immunosuppression strategies, or switching from a high-risk calcium channel blocker to another antihypertensive class.

• Medication change is not always possible or safe.
• Transplant patients must not stop cyclosporine without specialist direction.
• Epilepsy patients must not stop phenytoin abruptly.
• Hypertension and angina patients need medical blood pressure and cardiovascular protection.
• Dental prevention continues even if the drug cannot be changed.

• Severe bleeding, ulceration, necrosis, or rapidly changing tissue appearance
• Suspicion of malignancy, leukemia, or non-drug-related gingival enlargement
• Painful periodontal abscess or suppuration
• Severe enlargement interfering with nutrition, speech, airway, or oral hygiene
• Immunosuppressed patient with infection signs
• Uncontrolled periodontal infection in transplant or medically complex patients

• Plaque-induced inflammatory gingival enlargement
• Pregnancy-related gingival enlargement
• Leukemia-associated gingival enlargement
• Hereditary gingival fibromatosis
• Localized pyogenic granuloma
• Peripheral giant cell granuloma or fibroma
• Periodontal abscess or suppurative periodontal disease
• Gingival tumors or malignant lesions
• Systemic disease-related gingival changes

• Calling every gingival enlargement “inflammation” without reviewing medication history
• Blaming the medication and ignoring plaque control
• Stopping medication without physician approval
• Performing gingivectomy before controlling inflammation
• Failing to distinguish pseudo-pockets from true periodontal attachment loss
• Missing leukemia or malignant lesions in unusual gingival enlargement
• Ignoring recurrence risk after surgery
• Failing to communicate with the prescribing physician in severe cases

• Do not stop or change prescribed medication without the physician.
• Brush carefully along the gumline twice daily.
• Clean between the teeth daily with the method recommended by the dental team.
• Attend professional cleaning and periodontal maintenance regularly.
• Report bleeding, swelling, pus, loose teeth, or rapid gum growth.
• Tell the dentist when a new anticonvulsant, immunosuppressant, or blood pressure medication is started.
• Understand that gum surgery may be needed if fibrotic overgrowth remains after inflammation control.
• Expect recurrence if the medication continues and plaque control is poor.

Drug-induced gingival overgrowth is managed with a triangle: plaque control, medical communication, and periodontal therapy. If one side is missing, recurrence becomes much more likely.

• Phenytoin
• Cyclosporine
• Nifedipine
• Amlodipine
• Calcium Channel Blockers
• Periodontal Maintenance
• Gingivectomy
• Plaque-Induced Gingivitis
• Leukemia-Associated Gingival Enlargement
• Dental Management of Medically Complex Patients

Drug-induced gingival overgrowth is a medication-related enlargement of the gingiva most classically linked to phenytoin, cyclosporine, and calcium channel blockers such as nifedipine and amlodipine. It often starts at the interdental papillae, is worsened by plaque inflammation, and can create pseudo-pockets that trap more plaque. Dental management begins with medication history, periodontal charting, plaque control, professional debridement, and documentation. The dentist should communicate with the prescribing physician when medication substitution may be appropriate, but should never stop essential medication independently. Persistent fibrotic enlargement may require gingivectomy or periodontal surgery after inflammation is controlled. Red flags such as rapid unexplained enlargement, ulceration, necrosis, spontaneous bleeding, systemic illness, or suspicion of malignancy require urgent investigation.